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http://dx.doi.org/10.1016/j.ccr.2012.11.005SUMMARYIn human glioblastomas (hGBMs), tumor-propagating cells with stem-like characteristics (TPCs) represent
a key therapeutic target. We found that the EphA2 receptor tyrosine kinase is overexpressed in hGBM
TPCs. Cytofluorimetric sorting into EphA2High and EphA2Low populations demonstrated that EphA2 expres-
sion correlates with the size and tumor-propagating ability of the TPC pool in hGBMs. Both ephrinA1-Fc,
which caused EphA2 downregulation in TPCs, and siRNA-mediated knockdown of EPHA2 expression sup-
pressed TPCs self-renewal ex vivo and intracranial tumorigenicity, pointing to EphA2 downregulation as
a causal event in the loss of TPCs tumorigenicity. Infusion of ephrinA1-Fc into intracranial xenografts elicited
strong tumor-suppressing effects, suggestive of therapeutic applications.INTRODUCTION
Human glioblastoma multiforme (hGBM) is the most malignant
among gliomas. Because of their very heterogeneous cellular,
genetic, epigenetic, and molecular make-up (Maher et al.,
2001), hGBMs have a dismal prognosis and almost inevitably
recur (Krex et al., 2007; Chen et al., 2012).
Recent findings havedemonstrated the existence of a subpop-
ulation of hGBM cells, called cancer stem cells, whose idiosyn-Significance
Identification and characterization of key regulatory mechanis
apies for hGBMs. We show that TPCs overexpress EphA2 in h
undifferentiated state, supporting their self-renewal and tumor
like potential and tumor-propagating ability of TPCs from hGB
cell sorting. EphrinA1-Fc ligand-induced downregulation or siR
loss of self-renewal as well as induce differentiation and loss
cranial infusion of ephrinA1-Fc under settings that resemble pu
activity.
Cancratic properties make them resilient to standard therapies. First
identified in acute myeloid leukemia (Bonnet and Dick, 1997),
cancer stem cells, better defined as tumor-propagating cells
(TPCs; Kelly et al., 2007), have been isolated from a variety of
solid tumors (Ponti et al., 2005; Ricci-Vitiani et al., 2009; Buzzeo
et al., 2007). TPCs with both stem cell characteristics and tumor-
initiation and propagation ability have now emerged as key
players in hGBM pathogenesis (Hadjipanayis and Van Meir,
2009; Galli et al., 2004).ms in TPCs are crucial for the development of specific ther-
GBMs, which underpins their inherent ability to maintain an
igenicity. EphA2 abundance provides ameasure of the stem-
Ms. Thus, high EphA2 levels can be used to enrich TPCs by
NA-mediated knockdown of EPHA2 expression both cause
of tumor-initiating capacity in hGBM TPCs. Sustained intra-
tative therapeutic conditions elicits effective antitumorigenic
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Figure 1. The EphA2 Receptor in Human Glioblastoma Tissues and TPCs
(A and B) Example of strong and frequent EphA2 immunoreactivity (brown) in the tumor core (A, arrows) as compared to infrequent, weaker labeling in the
periphery (B) of the same hGBM specimen (six hGBMs yielded similar results). Insets: higher magnification. Bottom: no primary antibody. Blue, hematoxylin
counterstain. Scale bar, 20 mm. See also Figures S1A–S1C.
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EphA2 Drives GBM-Derived Tumor-Propagating CellsWhile the origin and nature of hGBM TPCs remain to be
unraveled, alterations of G1 arrest regulatory pathways in
Nestin- or GFAP-positive cells can cause the onset of high-grade
gliomas (Alcantara Llaguno et al., 2011). Thus, hGBM TPCs
might derive from the transformation of neural stem cells or their
transit amplifying precursor progeny (Alcantara Llaguno et al.,
2009; Vescovi et al., 2006). Oligodendroglial precursors might
also be the cell of origin in some hGBMs (Sukhdeo et al.,
2011). The peculiar characteristics of TPCs encompass a relative
quiescent nature, unlimited self-renewal, the clonal capacity to
found a tumor (Galli et al., 2004), and resistance to conventional
and multimodal treatments (Bao et al., 2006).
Owing to their stem-like nature, TPCs might be regulated by
the same cues that control the activity of normal neural precur-
sors and stem cells (NSCs). In fact, pathways that impinge on
self-renewal and cell fate in normal NSCs are also active in brain
tumors (Alcantara Llaguno et al., 2011; Dell’Albani, 2008). Also,
therapeutic agents targeting Wnt, Hedgehog, or Notch deplete
the TPC population in hGBMs (Takebe et al., 2011), and tumor
suppressor genes can regulate TPC self-renewal (Zheng et al.,
2008). The connection of TPCs with NSCs is reinforced by the
discovery that critical effectors of NSC activity in the brain
stem cell niche, such as bonemorphogenetic proteins, suppress
the growth of hGBM TPCs, enforcing their differentiation into as-
troglia (Lee et al., 2008; Piccirillo et al., 2006; Zhang et al., 2006).
Another key regulator in the adult NSC niche, nitric oxide, can
also drive TPC proliferation in hGBMs (Eyler et al., 2011).
Eph receptor tyrosinekinasesand their ephrin ligands influence
central nervous system development, stem cell niches, and can-
cer cells (Goldshmit et al., 2006;Genander andFrise´n, 2010; Pas-
quale, 2010). Deregulation of the Eph receptor/ephrin system is
associated with acquisition of tumorigenic properties, tumor
growth, angiogenesis, and metastasis in human cancers. In par-
ticular, EphA2 receptor is overexpressed in many human epithe-
lial malignancies and hGBMs, where it can promote proliferation
and invasiveness through mechanisms that are not well under-
stoodandmaybe independent of ephrin ligandbinding (Wykosky
and Debinski, 2008; Miao et al., 2009; Pasquale, 2010; Gopal
et al., 2011; Nakada et al., 2011; Miao and Wang, 2012). High
EphA2 expression also correlates with tumor stage, progression,
and patient survival (Wykosky et al., 2005; Liu et al., 2006; Wang
et al., 2008; Miao et al., 2009; Li et al., 2010; Wu et al., 2011).
In this study, we investigated the putative regulatory role and
function of the EphA2 receptor in TPCs from hGBMs.
RESULTS
High EphA2 Expression in hGBMs and Their TPCs
Analysis of hGBM surgery specimens showed high EphA2
mRNA expression as compared to other EphA and EphB recep-(C) Immunolabeling of hGBM tissue shows that cells positive for the putative neur
receptor (green; five hGBMs yielded similar results). Scale bar, 20 mm.
(D) Coexpression of EphA2 (green) and ephrinA1 (red) on the surface of cells in
pression (yellow). Scale bars, 10 mm.
(E) Higher EphA2 expression as detected by qPCR in cultured TPCs from the core
hGBM(non-TPCs;n=6 independentcultures;Student’s t test, p=0.017).Controls:
(F) TPCs differentiated by mitogen starvation show upregulation of astroglial (GF
[TH], glutamate, and GABA) markers (left), while losing EphA2 expression (right).
Cantors (Figure S1A available online). Real-time PCR (qPCR) re-
vealed how EphA2 mRNA levels were up to 100-fold higher in
hGBMs than in normal human brain tissue, as compared to
a 10-fold upregulation in low-grade gliomas, epitheliomas, and
primitive neuroectodermal tumors (Figure S1B).
Strong EphA2 immunoreactivity was found in many cells of the
non-necrotic hGBMcore (Figure 1A) versus a few positive cells in
the tumor periphery (Figure 1B) and normal brain (Figure S1C).
Accordingly, immunolabeling of hGBM tissues showed coex-
pression of EphA2 and antigens of normal and transformed
neural precursors, namely Nestin, Sox2, and Olig2 (Fatoo
et al., 2011; Ligon et al., 2007) (Figure 1C). In contrast, the signal
for ephrinA1, an EphA2 preferred ligand (Wykosky et al., 2008;
Miao et al., 2009), was variable in intensity and distribution in
the hGBM core and undetectable in the periphery (Figure S1C).
We also found high EphA2 mRNA and protein levels in cells
acutely dissociated from hGBMs or cultured as neurospheres
and enriched for the putative TPC markers SSEA-1 or CD44
(Figures S1D–S1F). Analysis of hGBM TPCs confirmed this over-
expression (Figure 1E), whichwas from 2- to 300-fold that of their
original hGBM tissue (Figure S1G). EphA2 and ephrinA1 were
detected in both hGBMs and their TPCs (Figure 1D). Notably,
EphA2 was heavily downregulated when TPCs were differenti-
ated, losing stemness and tumorigenicity (Piccirillo et al., 2006;
Zhang et al., 2006) (Figure 1F), reinforcing a correlation between
high EphA2 levels and the TPC state.
EphA2 mRNA levels in individual TPC neurosphere cultures
also correlated with their specific growth kinetics (Figures S1H
and S1I), i.e., with their self-renewal activity (Rietze and Rey-
nolds, 2006), and with EPHA2 gene copy number at the
1p36.12 locus (p < 0.0001) (Figures S1H and S1J).
Enriching for Cells with Enhanced Tumor-Propagating
Ability Based on EphA2 Expression
To reinforce the correlation between EphA2 enhanced levels and
the TPC state we FACS-sorted acutely isolated hGBM cells into
two distinct pools, expressing either high (EphA2High) or low
(EphA2Low) EphA2 levels, and then assessed their in vitro clono-
genicity and intracranial tumorigenic capacity. As expected,
the EphA2High fraction contained more clonogenic cells than
the EphA2Low fraction (Figure 2A) and mice implanted with
EphA2High cells showed a higher mortality (median survival
4 months) than those receiving EphA2Low cells (median survival
7 months) (Figure 2B). Limiting dilution intracranial transplanta-
tion using acutely dissociated EphA2High and EphA2Low cells
(Figures S2A–S2C) confirmed that high EphA2 levels are a hall-
mark of TPCs and can be used for their enrichment. In addition,
when primary hGBM cells were sorted based on their combined
expression of EphA2 and the putative TPC antigen SSEA-1
(Figures 2C and 2D), intracranial tumorigenicity was significantlyal stem cell markers Nestin, Sox2, or Olig2 (red) coexpress (arrows) the EphA2
hGBM tissues (left) and TPC cultures (right). Arrows mark examples of coex-
(TPCs; n = 14 independent cultures) versus cells from the periphery of the same
vhNSCsandhumanfibroblasts (HF). Errorbars:SEM.SeealsoFiguresS1D–S1J.
AP), oligodendroglial (GalC), and neuronal (b-Tub, MAP2, tyrosine hydroxylase
Scale bar, 20 mm
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Figure 2. Enrichment of the Stem-like Tumorigenic Pool Based on EphA2 Levels
(A) Viable (propidium iodide negative) tumor cells acutely isolated from hGBM specimens (top left) were sorted into EphA2High and EphA2Low fractions (bottom
left). The EphA2High fraction displayed higher clonogenic index than the EphA2Low fraction (right) (n = 4 tumors). Error bars: SEM; **p = 0.0004 for EphA2High versus
EphA2Low by Student’s t test.
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EphA2 Drives GBM-Derived Tumor-Propagating Cellshigher in EphA2High SSEA-1High than in EphA2Low SSEA-1Low
cells (Figure 2E). Similar results were obtained with EphA2High
CD44High and EphA2Low CD44Low cells (Figures S2D–S2F). By
applying the extreme limiting dilution analysis approach, we
were able to show that the frequency of tumor-initiating cells
(TICs) was always significantly higher in cell fractions with an
increased EphA2 expression, alone or in combination with
SSEA-1 or CD44 (Figure S2G). Finally, when EphA2High and
EphA2Low cultured TPCs were assayed for intracranial tumorige-
nicity in a limiting dilution assay, as few as 100 EphA2High cells
established large gliomas in 60 days, as compared to aminimum
requirement of 5,000 cells when using EphA2Low, below which
level tumorigenicity was negligible, even after 7 months (Figures
2F and 2G).
EphrinA1-Fc Downregulates EphA2 and Inhibits TPC
Growth and Expression of Neural Stem Markers
Due to the emerging correlation between high EphA2 expres-
sion and TPC state, we used ephrinA1-Fc (a soluble ephrinA1
dimer fused to Fc) to downregulate EphA2 (Wykosky et al.,
2005; Liu et al., 2007) and examined its effects on hGBM
TPCs. A dose-dependent EphA2 downregulation ensued, which
peaked at ephrinA1-Fc concentrations of 1–5 mg/ml, producing
up to 90% receptor depletion (Figure S3A). EphrinA1-Fc induced
a negligible EphA2 downregulation both in cells derived from the
hGBM periphery (non-TPCs)—bearing stem-like features but
negligible tumorigenicity (Piccirillo et al., 2009)—and v-myc-
immortalized, non-transformed hNSCs (vhNSCs; De Filippis
et al., 2007) (Figure 3A). Immunofluorescence assays confirmed
EphA2 loss in both acutely isolated and cultured TPCs upon
ephrinA1-Fc treatment (Figure 3B).
TPCs acutely isolated from hGBM specimens adhered to the
dish when treated with ephrinA1-Fc, losing their capacity to
grow and to generate stable TPC lines in the neurosphere assay
(Figures 3C, 3D, and 3G), an effect also seen in 14 established
TPC cultures (Figures 3E–3G, S3B, and S3C). In contrast,
ephrinA1-Fc had negligible effects on non-TPCs (Figure 3H)
and vhNSCs (Figure 3I). Hence, ephrinA1-Fc dowregulates
EphA2 and hinders the expansive growth of cells that possess
both stem cell characteristics and tumor-propagating ability.
EphrinA1-Fc Depletes the TPC Pool, Inhibits Self-
Renewal, and Induces Astroglial Differentiation
The effects of ephrinA1-Fc suggested that it might inhibit the
expansion of the TPC pool. This was emphasized by the ability
of ephrinA1-Fc to downregulate both EphA2 and the neural(B) Intracranial transplantation of 6 x 104 EphA2High or EphA2Low cells confirmed
p < 0.0001 for EphA2High versus EphA2Low; n = 8).
(C) Confocal images show widespread colocalization (arrowheads; yellow) of Ep
(D) Cells from the same hGBM were sorted and gated according to EphA2 and S
(E) Kaplan-Meier survival curves show that mice receiving intracranially 23 104 an
and 164 days, respectively) than mice receiving EphA2Low SSEA-1Low cells (56%
p < 0.0001 EphA2High SSEA-1High versus EphA2Low SSEA-1Low; n = 9). Survival wa
EphA2Low SSEA-1Low TPCs. See also Figure S2.
(F) Limiting dilution intracranial transplant of cultured, luciferase-tagged TPCs so
(bottom; 5,000, 1,000, and 100 cells per mouse) shows a higher tumor-initiating
**p = 0.002, EphA2High versus EphA2Low.
(G) Kaplan-Meier analysis shows that mice receiving EphA2High TPCs die earlier
EphA2High versus EphA2Low; n = 9).
Canprecursor markers Nestin, Sox2, or Olig2 (Figure 3J) that are
coexpressed in TPC spheroids. Also, FACS analysis showed
loss of the putative TPC markers SSEA-1, CD44 and CD133
(Dell’Albani, 2008; Fatoo et al., 2011) (Figure S3D), but not of
BMI-1 (Fatoo et al., 2011). Finally, ephrinA1-Fc depleted the
TPC side population (SP), thought to comprise stem-like cells
(Fukaya et al., 2010) (Figure S3E).
To confirm depletion of the TPC stem-like pool by ephrinA1-
Fc, we measured self-renewal ability in a clonogenic assay,
whereby single cells from acutely dissociated or from estab-
lished TPC lines were plated in single wells by automated
FACS and grown as neurospheres. EphrinA1-Fc drastically
decreased clonogenicity in TPCs but not in non-TPCs, slightly
increasing vhNSC clonogenicity (Figure 4A). Loss of self-
renewal was not caused by changes in cell cycling (Figure 4B)
or viability (Figure 4C). Notably, ephrinA1-Fc induced a marked,
time-dependent upregulation of the astroglial antigen GFAP,
without affecting the neuronal bIII tubulin and oligodendroglial
GalC markers (Figure 4D). Thus, ephrinA1-Fc hinders self-
renewal in TPCs in a non-cytotoxic way and increases astroglial
differentiation.
Molecular Regulation of TPCs Stemness by EphA2
We studied the molecular events underlying the changes in-
duced in hGBM TPCs by ephrinA1-Fc. EphrinA1-Fc transiently
increased EphA2 tyrosine phosphorylation, in a dose-dependent
manner, causing a strong and persistent downregulation of
EphA2 expression (Figure 4E). We also observed marked ERK
phosphorylation, which returned to basal levels after 24 hr,
amoderate increases in Akt and FAKphosphorylation (Figure 4E,
bottom panels), and reorganization of the actin cytoskeleton
(Figures 4F–4J).
Altogether, this suggested that EphA2 expression sustains
TPC self-renewal and that receptor loss played a causal role in
the depletion of the hGBM stem-like pool. To prove this, we
used a mixture of siRNAs to assess the effects of direct EphA2
downregulation (Figure 5A). EPHA2 silencing caused changes
consistent with loss of stemness and increased differentiation,
ie, (1) loss of clonogenicity (Figure 5B) and amplification rate (Fig-
ure 5C), (2) downregulation of putative stem cell markers (Fig-
ure 5E), and (3) increased GFAP expression (Figure 5F). These
changes were quite similar to those induced by ephrinA1-Fc
(Figures 3G, 3J, 4A, and 4D). Per se, EphA2 downregulation acti-
vated ERK in TPCs, as shown by a prominent increase in its
phosphorylation (Figures 5F and 5G). Feeble Akt and FAK activa-
tion were detected. Furthermore, when EphA2 levels began tothe much higher tumor-propagating capacity of the former (MC test, log-rank
hA2 (red) and SSEA-1 (green) in hGBM tissue. Scale bar, 20 mm.
SEA-1 levels.
d 13 104 EphA2High SSEA-1High purified TPCs die earlier (median survival: 135
and 67% survival at 200 days, respectively). MC and GBW tests, log-rank
s also shorter when implanting 43 104 EphA2High SSEA-1High as compared to
rted into EphA2High and EphA2Low pools (top). Light emission imaging analysis
ability of EphA2High versus EphA2Low TPCs. Error bars, SEM; ***p < 0.0001,
than mice receiving EphA2Low cells (MC and GBW tests, log-rank p < 0.0001
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Figure 3. EphA2 Downregulation by EphrinA1-Fc Inhibits In Vitro Proliferation and Depletes the Stem Cell-like Pool in hGBM TPCs
(A) (Top) Cells were treated with ephrinA1-Fc for 24 hr. EphA2 was heavily downregulated in TPCs but not vhNSCs and non-TPCs. (Bottom) FACS analysis and
flow cytometry quantitative data showing EphA2 downregulation in TPCs based on equivalent molecules of phycoerythrin (ME-PE) (n = 10 independent cultures);
error bars, SEM; **p < 0.005 by Student’s t test. See also Figure S3A.
(B) EphrinA1-Fc (5 mg/ml for 24 hr) downregulates EphA2 expression in TPCs acutely isolated from patients or from neurospheres (TPCs no. 8 shown as an
example), but not in vhNSCs. Scale bar, 20 mm.
(C–F) EphrinA1-Fc (5 mg/ml for 48 hr) triggers obvious morphologic changes (arrowheads) in acutely isolated TPCs (C, control; D, treated) or serially subcultured
TPC neurospheres (E, control; F, treated), promoting cell adhesion. Scale bar, 50 mm.
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ure 5A, arrow), TPCs growth and ERK phosphorylation also
began to normalize (Figures 5C, arrow, and 5F). siRNA-mediated
knockdown of EPHA2 expression in vhNSCs also inhibited
growth (Figure 5D), in contrast to ephrinA1-Fc treatment, which
neither inhibited growth nor downregulated EphA2 in these cells
(Figures 3A, 3B, and 3I). Transduction of TPCs with individual
EPHA2 siRNA, and rescue with a siRNA-resistant EPHA2
construct, confirmed these effects as the result of the EphA2
mRNA knockdown (Figure 5G). Importantly, inhibition of ERK
activation partially rescued loss in clonogenicity as induced by
EPHA2 siRNA, implicating ERK activation in the loss of TPC
stemness, as caused by EphA2 downregulation (Figure 5H).
Notably, EphA2 phosphorylation on Serine897 (Ser897) pro-
motes oncogenic activities of the receptor that do not depend
on its interaction with ephrin ligands (Miao et al., 2009). We de-
tected a strong signal for Ser897-phosphorylated EphA2 in the
hGBM core and in TPCs but not in the hGBM periphery, non-
TPCs or vhNSCs (Figure 6A). Furthermore, treatment with high
doses of soluble monomeric EphA2 extracellular domain that
block endogenous EphA2-ephrin interaction did not affect
GFAP levels or ERK activity in TPCs (Figure 6B). Thus, the effects
of EphA2 in TPCs appear to be independent from activation by
endogenous ephrinA ligands.
EphrinA1-Fc and EPHA2 Silencing by siRNAs Suppress
TPC Tumorigenicity In Vivo
The main effect of ephrinA1-Fc treatment or siRNA-mediated
EPHA2 silencing is the depletion of the tumorigenic hGBM
TPC pool, which ought to reduce their tumorigenic capacity
in vivo. To examine the in vivo effects of ephrinA1-Fc, we used
three experimental paradigms. hGBM TPCs were (1) treated
with ephrinA1-Fc in culture prior to transplantation (pre-treat-
ment), (2) treated starting immediately after transplantation (co-
treatment), or (3) allowed to establish sizeable tumors before
beginning treatment with ephrinA1-Fc (post-treatment). All three
protocols were evaluated in a subcutaneous xenograft model.
Furthermore, pre- and post-treatment protocols were also eval-
uated in an intracranial (orthotopic) xenograft model (Galli et al.,
2004; Piccirillo et al., 2006).
When TPCs were injected subcutaneously, ephrinA1-Fc in-
hibited growth in all three protocols (Figure 7A). Similar results
were obtained with the more complex, yet clinically more rele-
vant, orthotopic model. In the intracranial hGBM model, tumor
growth was greatly reduced in the pre-treatment settings, as
shown by quantitative imaging of luciferase-tagged hGBM
TPCs (luc-TPCs; Figures 7B left panels, 7C left, 7E, and 7F)
and by the increase in overall survival (Figure 7C, right). Impor-
tantly, ephrinA1-Fc infusion into the brain for 14 days by
means of osmotic mini-pumps also effectively suppressed the
growth of well pre-established hGBMs (Figures 7B middle
and right panels, 7D left, 7G, and 7H). Kaplan-Meier analysis(G–I) Acutely isolated TPCs cannot establish stable TPC primary lines if exposed t
TPCs (G); p < 0.0001 versus Control-Fc. Negligible inhibition of ephrinA1-Fc was o
8 and non-TPCs no. 8 are shown as representative examples); error bars, SEM.
(J) Coexpression of EphA2 (red) with the putative stem antigens Nestin, Sox2, or O
EphrinA1-Fc nearly abolishes expression of both EphA2 and the stem antigens. I
Unless otherwise indicated, the data are representative of three independent ex
Canrevealed a median survival of 130 days for mice receiving
ephrinA1-Fc versus 72 days for controls, infused with Fc (Fig-
ure 7D, right)—confirming the therapeutic efficacy of ephrinA1-
Fc administration.
Immunohistochemistry confirmed that EphA2, which was
high in TPC-derived, control intracranial hGBMs (Figure S4A),
strongly downregulated upon ephrinA1-Fc infusion (Figure S4B).
Control tumors contained numerous malignant cells (Fig-
ure S4C), whereas ephrinA1-Fc-treated ones contained few
neoplastic cells and many more differentiated elements (Fig-
ure S4D). Accordingly, ephrinA1-Fc-treated tumors embodied
a lower percentage of mitotic cells (Figures S4E and S4F) and
were significantly less vascularized than Fc-treated controls
(2-fold reduction in total vascular area, with less and smaller
blood vessels; Figures S4G and S4H and data not shown).
To determine if decreasing EphA2 receptor levels was suffi-
cient to inhibit hGBM tumorigenicity, we analyzed the effects
of siRNAs-mediated EPHA2 silencing on the in vivo tumor-prop-
agating ability of luc-TPCs, in comparison with luc-TPCs treated
with control-siRNAs or untreated ones. Knockdown of endoge-
nous EPHA2 suppressed the growth of TPC-derived intracranial
tumors (Figure 7I, top) and substantially increased overall sur-
vival (Figure 7I, bottom).
Given the prominent involvement of EphA2 in the pathogenic
mechanisms of hGBMs documented above, we analyzed the
TCGA data set (Network, 2008) for relative EphA2mRNA expres-
sion in hGBMsubcategories (Verhaak et al., 2010).We found that
the classical and mesenchymal subtypes had the highest EphA2
expression (Figure 8). In addition, when themesenchymal or pro-
neural subtypes were divided into two groups based on median
EphA2 expression, high EphA2 expression trended with poor
patient survival (mesenchymal: 10.9 versus 15.03 months, p =
0.0415 Mantel-Cox [MC], p = 0.0215 Gehan-Breselow-Wilcoxon
[GBW]; proneural: 9.9 versus 16.73 months, p = 0.2026 MC test,
p = 0.0411 GBW test). There was no significant correlation
between EphA2 and patient survival in the neural and classical
subtypes.
DISCUSSION
We describe a specific role for the EphA2 receptor in the patho-
genesis of hGBMs. We report how enhanced EphA2 expression
is a property of the TPCs in these cancers and show a causal
relationship between high EphA2 expression and the capacity
of these cells to expand their pool size and form hGBMs. Accord-
ingly, high levels of EphA2 expression can be used to enrich for
TPCs by FACS. Furthermore, treatment with a soluble form of the
EphA2 ligand, ephrinA1-Fc, hinders the self-renewal ability of
hGBM TPCs causing a drastic loss in their capacity to establish
and propagate hGBM phenocopies subcutaneously or intracra-
nially. We demonstrate that EphA2 receptor downregulation is
a causal event in the suppression of the tumor-propagatingo ephrinA1-Fc (G, red line), which also inhibits steady growth in pre-established
bserved in non-TPCs (H) and vhNSCs (I) (p < 0.005 versus Control-Fc; TPCs no.
See also Figures S3B and S3C.
lig2 (green) in TPC spheroids treated for 24 hr with Control-Fc or ephrinA1-Fc.
nsets: higher magnification. Scale bar, 40 mm. See also Figures S3D and S3E.
periments giving similar results.
cer Cell 22, 765–780, December 11, 2012 ª2012 Elsevier Inc. 771
Figure 4. EphrinA1-Fc Inhibits TPC Self-Renewal by Inducing a Differentiated Phenotype
(A) Clonogenic assays show a dose-dependent inhibition of self-renewal by ephrinA1-Fc in TPCs but not in non-TPCs and vhNSCs; error bars, SEM; ***p < 0.0001
versus Control-Fc cells.
(B) Up to 5 mg/ml ephrinA1-Fc does not alter TPC cell cycling, as determined by FACS analysis of BrdU incorporation; error bars: SEM.
(C) Cytofluorimetric Tunel analysis shows no induction of apoptosis in TPCs or non-TPCs treated with ephrinA1-Fc; error bars: SEM; **p < 0.005, *p < 0.05 versus
Control-Fc.
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causes EphA2 downregulation in hGBM orthotopic xenografts,
significantly hindering their growth and expansion in the brain,
even if these tumors are established ahead of ephrinA1-Fc
administration.
Aberrant expression of Eph receptors has been reported in
various cancers, including gliomas, and correlates with malig-
nancy (Wykosky and Debinski, 2008; Pasquale, 2010; Nakada
et al., 2011; Miao and Wang, 2012). In our survey of 12 hGBM
specimens, we found EphA2 to be the most upregulated of the
Eph receptors. This is consistent with the EphA2 overexpression
previously reported in most high-grade human gliomas, which
correlates with poor prognosis (Wykosky et al., 2005; Liu et al.,
2006; Wang et al., 2008; Miao et al., 2009; Li et al., 2010; Wu
et al., 2011), suggesting a role for EphA2 in the pathogenesis
of hGBMs.
While studies with glioma cell lines have implicated EphA2 in
cell growth and invasiveness (Wykosky et al., 2005; Liu et al.,
2006, 2007; Miao et al., 2009; Li et al., 2010; Gopal et al.,
2011), the identity and nature of the actual target cells in the
patients’ own GBM remain unclear. In addition, the cellular func-
tions affected by EphA2, the regulatory mechanisms underpin-
ning EphA20s actions in hGBMs pathophysiology, and the possi-
bility of manipulating this system to suppress glioma growth are
not well characterized. hGBMs contain subpopulations of cells
that act as stem-like TPCs, which have now been proven to
be crucial therapeutic targets (Chen et al., 2012). We found
that the EphA2 receptor is coexpressed with neural precursor
markers in hGBMs, being concentrated in regions rich in TPCs.
Furthermore, hGBM cell preparations enriched in TPCs display
enhanced EphA2 levels which, conversely, are low in low-grade
gliomas (Figure S1B) that contain few TPCs (Galli et al., 2004).
Altogether, these findings suggest that high EphA2 levels are
a distinguishing feature of hGBM TPCs.
Conclusive evidence to this idea came from fractionating
TPCs into EphA2Low and EphA2High populations, also in combi-
nation with high levels of the putative TPC markers. The highest
tumorigenic potential was associated with high EphA2 or com-
bined, high EphA2 SSEA-1 or EphA2 CD44 expression. Thus,
in vitro and in vivo limiting dilution experiments show that high
EphA2 expression can be exploited to obtain preparations highly
enriched in TPCs, which are capable of establishing intracranial
hGBMs by injection of as few as 100 cells.
Overexpression of EphA2 in TPCs suggests a role for this
receptor in hGBM pathogenesis. A first indication that EphA2
might drive the expansion of the TPC pool came from the signif-
icant correlation between the rate of self-renewal of multiple TPC
preparations and their EphA2 mRNA levels and EPHA2 gene
copy number. This was reinforced by the fact that EphA2 expres-(D) Quantitative FACS analysis shows a time-dependent increase in equivalent mo
(b-Tub) or oligodendroglial GalC markers in ephrinA1-Fc-treated TPCs; error ba
confirms a marked, time-dependent increase in GFAP under the same settings.
(E) (Top) Tyrosine phosphorylation of EphA2 immunoprecipitated from whole hGB
EphA2, ERK, Akt and FAK (Tyr397) expression and phosphorylation in TPCs treat
ephrinA1-Fc concentrations preferentially stimulate signaling, higher ones more
(F–J) (F) TPCs spread on Cultrex show an organized actin cytoskeleton and F-acti
higher magnification (H and I; arrowheads). (G and J) EphrinA1-Fc-treatment (5
junctions (arrowhead). Scale bar, 20 mm.
Unless otherwise indicated, the data are representative of three independent ex
Cansion decreases dramatically when hGBM TPCs lost their stem-
ness upon differentiation.
To verify the role of EphA2 in TPC self-renewal and amplifica-
tion, we first perturbed EphA2 by using the ephrinA1-Fc ligand
(Noblitt et al., 2004; Lee et al., 2011; Khodayari et al., 2011).
This treatment decreased the proliferation of both acutely iso-
lated and of serially subcultured hGBM TPCs, was coupled to
the failure of primary hGBM TPCs to generate stably expanding
lines and caused both loss of expansion capacity and clono-
genic ability in well-established TPC cultures.
The ephrinA1-Fc action was associated to decreased expres-
sion of putative hGBM TPC antigens (such as Olig2, Nestin,
Sox2, CD133, CD44, and SSEA-1), occurred in the absence of
detectable changes in cell cycle or apoptosis and produced
increased astroglial differentiation and the depletion of the che-
moresistant SP. Notably, these effects were specific to TPCs,
since stem-like cells from the same tumors but lacking tumor-
propagating ability (non-TPCs) and nontransformed neural
stem cells (vhNSCs) were resilient to ephrinA1-Fc administra-
tion. Thus, in vitro exposure to ephrinA1-Fc leads to the deple-
tion of those stem-like cancer cells that are responsible for
hGBM initiation, growth, and recurrence after therapy.
EphrinA1-Fc caused prolonged EphA2 downregulation in
TPCs, suggesting a critical role for this phenomenon in this
ligand’s tumor suppressor activities. Although ephrin Ligands
trigger Eph receptor tyrosine phosphorylation and activation,
thereby eliciting complex downstream signaling, they also cause
Eph receptor downregulation (Wykosky et al., 2005; Liu et al.,
2007; Pasquale, 2010). We observed only negligible inhibition
of TPC clonogenicity (less than 10%; data not shown) at the
lower ephrinA1-Fc concentrations tested, which induced strong
intracellular signaling but limited EphA2 downregulation. Con-
versely, at higher ephrinA1-Fc concentrations, signaling was
weaker, but EphA2 downregulation, inhibition of TPC clonoge-
nicity and growth were much more evident. Indeed, while sig-
naling was transient and returned to basal levels within 24 hr,
the inhibition of TPC tumorigenicity and EphA2 downregulation
persisted well beyond 24 hr. The importance of EphA2 down-
regulation was further supported by the observation that in
vhNSCs ephrinA1-Fc failed to both induce EphA2 downre-
gulation and inhibit cell growth and self-renewal. Furthermore,
siRNA-mediated knockdown of EPHA2 expression closely
mimicked the effects of ephrinA1-Fc on TPC self-renewal, ex-
pansion, differentiation in vitro, and tumorigenic ability in vivo.
Interestingly, EPHA2 expression knockdown also inhibited
the growth and self-renewal of the ‘‘ephrinA1-Fc-resilient’’
vhNSCs. Therefore, EphA2 downregulation alone can inhibit
TPC tumor-propagating activity although it remains possible
that ephrinA1-Fc-induced EphA2 signaling may also contributelecules of fluorescein (ME-FITC) for astroglial GFAP but not neuronal bIII tubulin
rs, SEM; *p = 0.0095, **p = 0.0005 versus Control-Fc. (Inset) Western blotting
M lysates and from TPCs treated with ephrinA1-Fc. (Bottom) Western blots for
ed with increasing ephrinA1-Fc concentrations over a 24 hr time course. Lower
rapidly downregulate the receptor.
n assembled in stress fibers (arrows). Typical ring-like actin bundles are seen at
mg/ml for 5 min) causes TPC elongation and actin concentration at cell-cell
periments giving similar results.
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Figure 5. EPHA2 siRNA Knockdown in hGBM TPCs Inhibits Self-Renewal and Increases Differentiation, Concomitant with ERK and Akt
Activation
(A) TPCs were treated with an EPHA2 siRNA pool, non-targeting control (NTC) or GAPDH control pool siRNAs. Three days post-transfection, only the EPHA2
siRNAs caused a substantial decrease in EphA2 mRNA, as detected by qPCR. Between 12 and 16 days post-transfection (DIV), EphA2 levels began to normalize
(arrow); error bars, SEM.
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ski, 2008; Nakada et al., 2011; Miao and Wang, 2012). Thus,
EphA2 is prominently expressed in TPCs and is required for sus-
tained self-renewal and expansion of this tumor-propagating cell
pool in hGBMs.
The depletion of the TPC stem-like pool induced by ephrinA1-
Fc treatment and EphA2 downregulation seems to arise from
increased cell differentiation. First, loss of the undifferentiated
state is demonstrated by the depletion of Sox2, Olig2, Nestin,
CD133, CD44, and SSEA-1, as well as the increased expression
of the astroglial marker GFAP, as induced by both ephrinA1-Fc
and knockdown of EPHA2 expression. Second, both manipula-
tions also inhibit the typical undifferentiated stem-like functions
of TPCs, such as self-renewal and extensive amplification
capacity. Given the unchanged cell cycling and death rate, these
data imply that ephrinA1-Fc and EphA2 downregulation cause
the loss of undifferentiated functional and antigenic properties
as well as the acquisition of a more mature cell phenotype
by TPCs.
The activities of EphA2 in hGBM TPCs appear to involve
unconventional ephrin-independent activities of EphA2, which
are not yet well understood but may also involve crosstalk with
other signaling systems (Miao et al., 2009; Pasquale, 2010; Go-
pal et al., 2011; Miao and Wang, 2012). This is supported by the
prominent phosphorylation of EphA2 at the Ser897 residue (Miao
et al., 2009) that we detected in the TPC-enriched core but not
the periphery of hGBMs, and in cultured TPCs but not non-
TPCs or vhNSCs. Phosphorylation of EphA2 Ser897 by Akt is
known to promote EphA20s oncogenic activities independently
of ephrin binding, and in fact interaction of EphA2 with ephrinA1
inhibits phosphorylation at this site (Miao et al., 2009). Consistent
with a role of EphA2 in TPCs that does not depend on activation
by endogenous ephrins, using the soluble EphA2 extracellular
domain to block EphA2-ephrin interaction did not affect GFAP
levels or ERK activation in TPCs. In contrast, EPHA2 siRNA-
mediated knockdown depleted the stem cell pool concomitantly
with ERK, suggesting that this pathway may mediate the effects
of EphA2. This was confirmed by using the ERK inhibitor UO126,
which re-established self-renewal ability in TPCswith downregu-
lated EphA2 expression. This suggests that ERK can promote
differentiation in TPCs that have lost EphA2 expression.
The hindrance of self-renewal capacity induced by ephrinA1-
Fc predicts that this ligand will lessen the ability of TPCs to
establish tumors in vivo. In fact, a 48 hr exposure to soluble
ephrinA1-Fc reduced the capacity of TPCs to establish hGBM(B) siRNA-mediated knockdown of EPHA2 expression causes loss of TPC clono
(C) TPC growth decrease is concomitant with siRNA-mediated EphA2 downregula
p < 0.0001 EPHA2 siRNAs versus NTC.
(D) siRNA-mediated EphA2 downregulation decreased vhNSCs growth; error bars
upon EPHA2 siRNA treatment.
(E) Confocal analysis shows that siRNA-mediated EphA2 downregulation in TPC s
NTC-treated spheroids (NTC siRNAs). Insets: magnification. Scale bar, 40 mm.
(F and G) Western blot analysis show increased GFAP but not b-Tub or GalC leve
phosphorylation is also strongly increased concomitant with EphA2 downregulatio
to recover. (G) Representative western blot showing that only the siRNA sequen
activate ERK. An EPHA2 construct lacking the 30UTR sequence targeted by EPH
(H) The reduced TPC clonogenicity caused by knockdown of EPHA2 expression
***p < 0.0001, **p < 0.005 versus untreated TPCs.
Unless otherwise stated, data are representative of three independent experime
Canphenocopies, both subcutaneously and intracranially. A similar
effect was observed when we implanted TPCs subcutaneously
and began ephrinA1-Fc infusion either at the same time or after
sizeable tumors had been established. Treatment of intracranial
tumors with ephrinA1-Fc significantly reduced the tumor mass,
vascularization, and proliferation and dramatically decreased
EphA2 levels. When EPHA2 expression in TPCs was knocked
down with siRNAs, intracranial tumorigenicity was nearly abol-
ished. Thus, EphA2 is critical to maintain TPC properties and
plays a pivotal role in the pathogenesis of hGBMs in the brain,
as driven by TPCs.
Our findings are consistent with previous studies suggesting
that EphA2 expression correlates with malignancy in hGBMs
(Liu et al., 2006; Wang et al., 2008; Li et al., 2010; Wu et al.,
2011). Hence, we examined the relationship between EphA2
expression and patient survival in relation to the recent stratifica-
tion of hGBMs into different subtypes (Verhaak et al., 2010). We
found that EphA2 is most highly expressed in the classical and
mesenchymal groups and that, at least in the mesenchymal
subtype, patients with EphA2 levels above the median trended
toward poorer survival. This trend was also present and statisti-
cally significant in the proneural subtype, although this subtype
has lower mean levels of EphA2 than themesenchymal and clas-
sical ones. The correlation with poor survival in these two groups
further underscores the importance of EphA2 expression in
aggressive tumor behavior, which may be more relevant in the
mesenchymal and proneural hGBM subtypes.
We were able to drastically inhibit the growth of pre-existing
orthotopic hGBM xenografts under experimental conditions
that mimic those needed for experimental human therapy,
such as protracted delivery through intra-parenchymal infusion.
This supports the value of devising anti-GBM therapies that
harness the Eph/ephrin system to target the TPC compartment.
Hence, the concept emerges of impinging in non-toxic fashion
on specific molecular targets, such as EphA2, to tackle the
subset of tumor cells that plays the most critical role in hGBM
pathogenesis.
We show that a signaling system that is operational in the
neural stem cell niche also regulates self-renewal and tumorige-
nicity in hGBM TPCs, in agreement with previous observations
(Ying et al., 2011). Eph receptors and ephrins regulate the migra-
tion, survival, proliferation, cell fate and differentiation of neural
precursors during development (Goldshmit et al., 2006; Gen-
ander and Frise´n, 2010). In the adult, such activities persist in
stem cell niches, including those of the adult central nervousgenicity; error bars, SEM; **p < 0.005 EphA2 versus NTC siRNAs.
tion and normalizes when EphA2 levels begin recover (arrow); error bars, SEM;
, SEM; ***p < 0.0001 EPHA2 siRNAs versus NTC. Inset: western blot for EphA2
pheroids is associatedwith depletion of putative stemmarkers, as compared to
ls in TPCs treated with EPHA2 siRNAs versus NTC or GAPDH siRNAs (F). ERK
n, withmore prominent effects at 72 hr than at 5 days, when EphA2 levels begin
ces that effectively reduce EphA2 expression increase GFAP expression and
A2 siRNA no. 3 was used to transfect TPCs in a control rescue experiments.
was partially restored by 10 mM UO126, which inhibits ERK; error bars, SEM;
nts giving similar results.
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Figure 6. EphA2 Does Not Appear to be
Activated by Ephrins in hGBM
TPC is phosphorylated on Ser897 in hGBM and
treatment with the soluble EphA2 extracellular
domain to inhibit ephrin binding to endogenous
EphA2 does not affect TPC signaling pathways.
(A) Top: EphA2 is constitutively phosphorylated
on Ser897 in the core of hGBMs (left) but not in
the periphery of hGBMs (center) or normal brain
(right). Bottom: EphA2 is highly phosphorylated
on Ser897 in hGBM TPCs but not non-TPCs or
vhNSCs. EphA2 Ser897 phosphorylation suggests
ephrin-independent oncogenic activities.
(B) Representative western blots showing that
treatment of TPCs with 10 mg/ml EphA2 extracel-
lular domain to inhibit possible interactions with
endogenous ephrin ligands does not affect GFAP
levels or ERK phosphorylation as compared to Fc
protein used as a control.
Data are representative of three independent
experiments giving similar results.
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functions in adult neurogenesis remains limited. Since other
Eph receptors besides EphA2 are expressed in adult neural
stem cell niches (Goldshmit et al., 2006; Genander and Frise´n,
2010), by using agents that selectively target EphA2 we may776 Cancer Cell 22, 765–780, December 11, 2012 ª2012 Elsevier Inc.be able to target stem-like cells in hGBMs
without affecting the normal brain stem
cell population.
These findings emphasize the impor-
tance of approaches that exploit funda-
mental similarities in the physiology of
normal neural stem cells and their stem-
like, tumor-propagating counterpart in
brain tumors (Vescovi et al., 2006). Such
approaches can make use of the wealth
of information derived from studies on
regulatory systems in normal neural
stem cells to identify candidate effectors
capable to affect TPCs, thus helping to
design more effective and specific anti-
GBM therapies.
EXPERIMENTAL PROCEDURES
Primary Culture, Culture Propagation,
Population Analysis, and Cloning
Adult hGBM, low-grade gliomas, ependimomas,
PNET tissues, and normal human brain samples
were obtained and classified according to the
World Health Organization guidelines. All of the
tumors were banked in accordance with research
ethics board approval from the Institute of Neuro-
surgery, Catholic University of the Sacred Heart
(Prot. RBAP10KJC5) and patients gave informed
consent prior to surgery. hGBM non-necrotic
core and periphery tissues were dissected and
digested in a papain solution (Worthington Bio-
chemical, Lakewood, NJ, USA). Primary stem-
like tumor-propagating cells (acutely isolated
cells) were plated in NeuroCult NS-A medium(StemCell Technologies, Vancouver, BC, Canada) containing 20 ng/ml of
epidermal- and 10 ng/ml of fibroblast-growth factor (Peprotech, Rocky Hill,
NJ, USA) (culture medium; Galli et al., 2004). EphA2 was stimulated with
ephrinA1-Fc (R&D Systems, Minneapolis, MN, USA) for the indicated concen-
trations and times. Mouse monoclonal IgG1 isotype (R&D Systems) was used
as control. For population analysis, clonogenic assays and differentiation
Figure 7. EphA2 Downregulation by EphrinA1-Fc or by siRNA-Mediated Knockdown Inhibits TPC Tumorigenicity in Immunodeficient Mice
(A) Treating TPCs with ephrinA1-Fc (5 mg/ml for 48 hr) prior to subcutaneous implantation (PRE-treatment) lessens their tumor-initiating capacity (left). Similar
results were obtained by coinjecting TPCs and ephrinA1-Fc (CO-treatment) or injecting ephrinA1-Fc (10 mg/day) around the tumor starting 11 days after cell
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Figure 8. EphA2 Is Differentially Expressed
in GBMSubtypes, and Its Abundance Corre-
lates with Patient Survival
(A) Relative EphA2 mRNA expression in the four
GBM sutbypes of the TCGA data set. (***p <
0.0001 by ANOVA; n = 495).
(B) Kaplan-Meier survival curves for the classical,
mesenchymal, proneural, and neural subtypes.
High and low expression are defined as above
and below the median expression value for each
subtype, log-rank p values were determined by
MC and GBW tests.
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Procedures.
Statistical Analysis for the Correlation
Growth curves were analyzed with a hierarchical linear model for repeated-
measurements to assess trend over time (Diggle et al., 1994; Singer and Wil-transplant (POST-treatment). (Right) Volumes of subcutaneous tumors 35 days after TPCs injection. Histo
Control-Fc mice, n = 6.
(B) Imaging of luciferase-tagged TPCs (luc-TPCs) injected into the brain of Scid/bg mice. After 42 days, untr
left) than ephrinA1-Fc PRE-treated TPCs (bottom left). Luc-TPC tumors established for 7 days (7 DPT, top
Control-Fc for 14 days starting at 11 days post-transplant (27 DPT, bottom center). In contrast, tumor growt
bottom right panels).
(C) (Left) Quantitative analysis of luc-TPC signals for the PRE-treatment intracranial transplants. Histograms, m
n = 6. (Right) Kaplan-Meier survival curves showing that mice receiving ephrinA1-Fc-treated TPCs have a
Control-Fc cells (MC and GBW tests, log-rank p = 0.0005 and 0.0013 respectively; n = 9).
(D) (Left) Quantitative time course analysis of the luc-TPC signal for POST-treatment paradigm (arrows mark
mean ± SEM; *p < 0.05 versus Fc-treated mice; n = 8. (Right) Kaplan-Meier survival curves are shown (MC a
versus Control-Fc mice; n = 9).
(E–H) Mouse brain sections immunolabeled for luciferase show that tumors established from luc-TPCs PRE-t
parenchymamore than those established from cells PRE-treated with ephrinA1-Fc (F) at 42 DPT. Similarly, ep
11 days after tumor establishment (H) inhibits the growth of luc-TPC tumors more than Control-Fc (G). Arrow
callosum; LV, lateral ventricle; St, striatum. See also Figure S4. Scale bar, 1 mm.
(I) Loss of intracranial tumorigenicity in luc-TPCs treated with EPHA2 siRNAs for 72 hr prior to transplantatio
TPCs. Tumor growth was monitored by quantitative imaging analysis (top). Histograms, mean ± SEM; ***p <
Kaplan-Meier survival analysis. Mice receiving EPHA2 siRNA-transfected TPCs die significantly later than th
with non-targeting control siRNAs (MC and GBW tests, log-rank p < 0.0001 versus NTC siRNAs treatment;
778 Cancer Cell 22, 765–780, December 11, 2012 ª2012 Elsevier Inc.lett, 2003). Log-transformed cell number was
considered as outcome. Association with EphA2
mRNA expression levels and EPHA2 copy number
were assessed including them into the statistical
models (Figures S1H–S1J). A spatial power corre-
lation type was used to account for unequally
spaced time occasions during the experiment
(Singer and Willett, 2003). Unless indicated other-
wise, comparisons between ephrinA1-Fc (also
with different doses) treated cells and Control-
Fc-treated cellswere carried outwith a hierarchical
linear model for repeated-measurements. The
p values less than 0.05 were considered statisti-
cally significant. All analyseswere performed using
SAS Statistical Package Release 9.1 (SAS Insti-
tute, Cary, NC, USA) or GraphPad Prism.
Evaluation of Tumorigenicity by
Subcutaneous or Orthotopic Implantation
Tumorigenicity was studied by TPCs subcuta-
neous or orthotopic injections (Galli et al., 2004).
All animal procedures were conducted in accor-
dance with the Guidelines for the Care and Use
of Laboratory Animals and were approved by the
Institutional Animal Care and Use Committees(IACUCs) at the University of Milan Bicocca. See the matching section in the
Supplemental Experimental Procedures for details.
Molecular Analysis
TCGA data analysis was performed as described by Squatrito et al., 2010;
survival and expression data were based on clinical TCGA data and relativegrams, mean volume ± SEM; **p = 0.0002 versus
eated TPCs established larger tumors (vehicle, top
center) grew quickly when a mini-pump delivered
h was markedly inhibited by ephrinA1-Fc (top and
ean ± SEM; ***p < 0.0001 versus Control-Fc mice;
significant longer life span than mice injected with
the time of mini-pumps implantation). Histograms,
nd GBW tests, log-rank p < 0.0001 and p = 0.0002
reated with Control-Fc (E) spread through the brain
hrinA1-Fc infused into the brain for 2 weeks starting
heads mark the edges of the tumors. CC, corpus
n as compared to NTC siRNA-treated or untreated
0.0001 EPHA2 siRNAs versus NTC; n = 6. (Bottom)
ose receiving untreated TPCs or TPCs transfected
n = 9).
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EphA2 Drives GBM-Derived Tumor-Propagating CellsmRNA expression obtained from the TCGA data portal (http://cancergenome.
nih.gov/dataportal/data/about) and the MSKCC cBio Genome Data Analysis
Portal (http://cbio.mskcc.org/gdac-portal/index.do), respectively. Tumor
subtype classificationwas previously described (Verhaak et al., 2010). Relative
mRNA results are based on relative distribution of the expression values for
diploid tumor samples and were subjected to statistical analysis by one-way
ANOVA (GraphPad Prism v5.0 software). Survival curves were analyzed using
the Kaplan-Meier method, with groups compared by respective median
survival of number of days taken to reach 50% morbidity; log-rank p value
was measured using both MC and GBW tests.
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